Endo Pharmaceuticals to price $400 million 10-year notes Thursday

By Paul A. Harris

St. Louis, Nov. 15 - Endo Pharmaceuticals Holdings Inc. plans to price a $400 million offering of 10-year senior notes on Thursday, according to an informed source.

J.P. Morgan Securities LLC, RBC Capital Markets Corp. and Barclays Capital Inc. are the joint bookrunners for the Rule 144A and Regulation S offering.

The Chadds Ford, Pa.-based pharmaceutical company will use the proceeds to partially finance the pending acquisition of Qualitest Pharmaceuticals or for general corporate purposes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.